Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 443

1.

Posttransplant administration of cyclophosphamide and donor lymphocyte infusion induces potent antitumor immunity to solid tumor.

Eto M, Kamiryo Y, Takeuchi A, Harano M, Tatsugami K, Harada M, Kiyoshima K, Hamaguchi M, Teshima T, Tsuneyoshi M, Yoshikai Y, Naito S.

Clin Cancer Res. 2008 May 1;14(9):2833-40. doi: 10.1158/1078-0432.CCR-07-1742.

2.

Renal cancer treatment with low levels of mixed chimerism induced by nonmyeloablative regimen using cyclophosphamide in mice.

Harano M, Eto M, Iwai T, Tatsugami K, Kiyoshima K, Kamiryo Y, Tsuneyoshi M, Yoshikai Y, Naito S.

Cancer Res. 2005 Nov 1;65(21):10032-40.

6.

Allogeneic cell therapy from immunized donors with tumor antigen peptide enhances the antitumor effect after cyclophosphamide-using non-myeloablative allogeneic hematopoietic cell transplantation.

Hamaguchi M, Eto M, Kamiryo Y, Takeuchi A, Harano M, Tatsugami K, Teshima T, Harada M, Yoshikai Y, Naito S.

Cancer Sci. 2009 Jan;100(1):138-43. doi: 10.1111/j.1349-7006.2008.01014.x. Epub 2008 Nov 24.

7.

Cyclophosphamide-using nonmyeloablative allogeneic cell therapy against renal cancer with a reduced risk of graft-versus-host disease.

Eto M, Harano M, Tatsugami K, Harada M, Kamiryo Y, Kiyoshima K, Hamaguchi M, Tsuneyoshi M, Yoshikai Y, Naito S.

Clin Cancer Res. 2007 Feb 1;13(3):1029-35.

8.
10.

Renal cancer treatment with recipient lymphocyte infusion enhanced the antitumor effect of nonmyeloablative allogeneic stem cell transplantation.

Takeuchi A, Eto M, Tatsugami K, Yamada H, Yokomizo A, Shiota M, Itsumi M, Inokuchi J, Kiyoshima K, Dejima T, Imada K, Naito S, Yoshikai Y.

Transpl Immunol. 2015 Mar;32(2):131-9. doi: 10.1016/j.trim.2014.12.001. Epub 2014 Dec 16.

PMID:
25527449
11.

[Effects of sensitized donor lymphocyte infusion on the chimerism and graft-versus-host disease after nonmyeloablative allogeneic stem cell transplantation].

Chen BA, Zhang Y, Ding JH, Bi YZ, Zhao G, Gao C, Sun YY, Sun XM, Wang J, Chen NN, Cheng J.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Feb;14(1):102-6. Chinese.

PMID:
16584602
15.

Blockade of the CD40/CD154 pathway enhances T-cell-depleted allogeneic bone marrow engraftment under nonmyeloablative and irradiation-free conditioning therapy.

Pan Y, Luo B, Sozen H, Kalscheuer H, Blazar BR, Sutherland DE, Hering BJ, Guo Z.

Transplantation. 2003 Jul 15;76(1):216-24.

PMID:
12865813
16.
17.

Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets.

Stelljes M, Strothotte R, Pauels HG, Poremba C, Milse M, Specht C, Albring J, Bisping G, Scheffold C, Kammertoens T, Oelmann E, Silling G, Berdel WE, Kienast J.

Blood. 2004 Aug 15;104(4):1210-6. Epub 2004 Apr 15.

18.

Allogeneic MHC gene transfer enhances antitumor activity of allogeneic hematopoietic stem cell transplantation without exacerbating graft-versus-host disease.

Ohashi M, Kobayashi A, Hara H, Miura Y, Yoshida K, Kushida M, Ikarashi Y, Mandai M, Kitajima M, Yoshida T, Aoki K.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2208-15.

19.

Donor CD4 T cells are critical in allogeneic stem cell transplantation against murine solid tumor.

Kamiryo Y, Eto M, Yamada H, Yajima T, Harano M, Takeuchi A, Tatsugami K, Hamaguchi M, Naito S, Yoshikai Y.

Cancer Res. 2009 Jun 15;69(12):5151-8. doi: 10.1158/0008-5472.CAN-08-2517. Epub 2009 Jun 2.

20.

Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.

Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ.

N Engl J Med. 2000 Sep 14;343(11):750-8.

Items per page

Supplemental Content

Write to the Help Desk